Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts
Our results suggest a prognostic role of IDO-1 protein expression in NSCLC tumor and immune cells independent of EGFR, KRAS AND PD-L1 expression, and should be explored as a predictive biomarker in clinical studies with IDO-1 targeted therapies.
Authors
- Paul Mitchell (ORCID: https://orcid.org/0000-0003-2470-3790)
- Shengxiang Ren (ORCID: https://orcid.org/0000-0001-8767-9850)
- Francesco Agustoni (ORCID: https://orcid.org/0000-0002-4334-1230)
- Gareth Rivalland
- Dexiang Gao (ORCID: https://orcid.org/0000-0003-3920-7060)
- Rafał Dziadziuszko (ORCID: https://orcid.org/0000-0001-8080-9843)
- Derek Smith (ORCID: https://orcid.org/0000-0001-8117-2477)
- Christopher J. Rivard
- Paolo Pedrazzoli (ORCID: https://orcid.org/0000-0002-9419-7160)
- Salvatore Corallo (ORCID: https://orcid.org/0000-0002-6672-0233)
- Fred R. Hirsch (ORCID: https://orcid.org/0000-0002-6885-1894)
- Hui Yu (ORCID: https://orcid.org/0000-0003-2288-4671)
- Íñigo San Millán
- Kim Ellison
Institutions
- Tongji University (CN)
- Mount Sinai Health System (US)
- University of Pavia (IT)
- Shanghai Pulmonary Hospital (CN)
- Tisch Hospital (US)
- University of Colorado Cancer Center (US)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Colorado Anschutz Medical Campus (US)
- Gdańsk Medical University (PL)
- University of Colorado Colorado Springs (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1586782
- Citations
- 1
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.58
Funders
- Fondazione IRCCS Policlinico San Matteo